CD163 and COVID-19: In the present study, in a cohort of patients with different COVID-19 severity, we longitudinally investigated the levels of brain injury (NfL and GFAP), myeloid activation marker (sCD163) and in turn, implications for the CNS during the acute stage of the disease and three months after hospital discharge.